A Madison company earns itself a $4 million federal grant for developing a therapeutic human skin substitute.
Statatech Corporation won the grant for development of a substitute that would help treat a type of skin ulcer that is a life-threatening complication of diabetes. Those skin ulcers can result in poor blood flow, infections and amputation.
The National Institutes of Health awarded Stratatech the grant from the National Institute of Diabetes and Digestive and Kidney Diseases.
 |
 |
 |
